| Patent Number |
Title Of Patent |
Date Issued |
| 6905818 |
Method for the identification and characterization of interacting molecules by automated interac |
June 14, 2005 |
| The present invention relates to an improved method for the identification and optionally the characterisation of interacting molecules designed to detect positive clones from the rather large numbers of false positive clones isolated by conventional two-hybrid systems. The method of the |
| 6897029 |
MCK-10 a novel receptor tyrosine kinase |
May 24, 2005 |
| The present invention relates to the novel family of receptor tyrosine kinases, herein referred to as MCK-10, to nucleotide sequences and expression vectors encoding MCK-10, and to methods of inhibiting MCK-10 activity. The invention relates to differentially spliced isoforms of MCK- |
| 6200768 |
Method of screening for compounds that dissolve paired helical filaments |
March 13, 2001 |
| The invention relates to epitopes of the protein which are specifically occurring in a phosphorylated state in tau protein from Alzheimer paired helical filaments, to protein kinases which are responsible for the phosphorylation of the amino acids of the tau protein giving rise to said |
| 6177401 |
Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
January 23, 2001 |
| The present invention relates to the use of proteins, peptides and organic molecules capable of modulating Flk-1 receptor signal transduction in order to inhibit or promote angiogenesis and vasculogenesis. The invention is based, in part, on the demonstration that Flk-1 tyrosine kinase |
| 6096521 |
Adhesin from Helicobacter pylori |
August 1, 2000 |
| The present invention concerns an adherence gene from Helicobacter pylori, a polypeptide coded thereby and antibodies against the polypeptide. |
| 6051397 |
DNA encoding MCK-10, a novel receptor tyrosine kinase |
April 18, 2000 |
| The present invention relates to the novel family of receptor tyrosine kinases, herein referred to as MCK-10, to nucleotide sequences and expression vectors encoding MCK-10, and to methods of inhibiting MCK-10 activity. The invention relates to differentially spliced isoforms of MCK- |
| 5980915 |
Process for the production of a pharmaceutical agent for oral or topical administration in the t |
November 9, 1999 |
| The invention concerns a new pharmaceutical agent for oral or topical administration in the treatment of protozoal diseases, in particular of leishmaniasis, which contains as the active substance one or several compounds having the general formula I ##STR1## in which R.sup.1 is a |
| 5954930 |
Reference electrode for electrolytic cells having an ion-conducting solid electrolyte |
September 21, 1999 |
| The invention relates to a reference electrode for electrolytic cells having an ion-conducting solid electrolyte, to sensors comprising the reference electrode of the invention and to their use of the reference electrode for analyzing gases. |
| 5856447 |
Hybridomas producing antibodies specific for lyme disease antigens OspA and OspB |
January 5, 1999 |
| The present invention provides a vaccine against Lyme disease, wherein it contains one or more monoclonal antibodies which are specific for the 31 kD antigen (OspA) or the 34 kD antigen (OspB) of Borrelia burgdorferi.The present invention also provides a process for obtaining this vaccine, |
| 5396089 |
Method of generating active semiconductor structures by means of starting structures which have |
March 7, 1995 |
| A unipolar electronic component is proposed with a quasi one dimensional carrier channel which has all the characteristics of an FET. This component can be very simply produced, has "self-alignment" and linear gates with a low capacity in place of planar gates. In this way a very hig |
| 5385865 |
Method of generating active semiconductor structures by means of starting structures which have |
January 31, 1995 |
| A novel unipolar transistor device has been realized starting from two-dimensional electron systems (2DES) in modulation-doped AlGaAS/GaAs heterostructures. A 600 nm wide 1D channel is insulated laterally from 2DES regimes by 700 nm wide deep mesa etched trenches. The conductivity in |
| 5060234 |
Injection laser with at least one pair of monoatomic layers of doping atoms |
October 22, 1991 |
| A semiconductor device consisting of epitaxial material is provided with at least one monoatomic layer of doping atoms, i.e. with a layer which is just one atom thick. A particularly preferred device is injection laser in which case the Dirac-delta doped layers 45 and 46 are within intri |
| 5057431 |
Device for optical measuring of physical dimensions and material concentrations |
October 15, 1991 |
| An optode designed to prevent washing away of the indicator and reagent from a membrane is located within an optical device that measures substance concentrations. The reagent and indicator materials are covalently bound on the membrane. The membrane can be a polysaccharide, especial |
| 4994493 |
N-substituted 5-nitroanthranilic acids, a process for their preparation, their use, and pharmace |
February 19, 1991 |
| Compounds I ##STR1## with R equal to hydrogen or (C.sub.1 -C.sub.4)-alkyl,X equal to (CH.sub.2).sub.n with n=1-4, unsubstituted or substituted, andAr is equal to an aromatic or heteroaromatic system, optionally substituted,and their pharmaceutically tolerated salts are valuable pharmaceu |
| 4921875 |
Use of amino-substituted benzoic acids as remedies for diarrhea, and medicaments based on these |
May 1, 1990 |
| A description is given of the use of amino-substituted benzoic acid derivatives of the formula I ##STR1## in which R.sup.1 and R.sup.2 denote hydrogen, (cyclo)alkyl, unsubstituted or substituted phenyl or naphthyl, or R.sup.1 and R.sup.2 together denote a chain --(CH.sub.2).sub.m |
| 4610815 |
Process for producing and obtaining anaphylatoxin- and cocytotaxin-containing leucotaxine prepar |
September 9, 1986 |
| The invention relates to a process for producing and obtaining anaphylatoxin- and cocytotaxin-containing leucotaxine preparations and anaphylatoxin and cocytotaxin proteins in molecularly homogeneous, biologically active form from contact-activated mammalian serum by the following st |
| 4552761 |
Method for influencing the immune systems of mammals using leukorecruitin |
November 12, 1985 |
| The invention relates to SERUM-DERIVED "LEUKORECRUITIN", which is A PROTEIN MEDIATOR OF INFLAMMATION FROM MAMMALIAN SERUM specifically inducing positive leukocytosis reaction and leukocyte recruitment from the bone marrow into the blood of animals and humans without biological side-r |
| 4525464 |
Ceramic body of zirconium dioxide (ZrO.sub.2) and method for its preparation |
June 25, 1985 |
| A ceramic body of zirconium dioxide containing, if desired, aluminum oxide, and partially stabilized with yttrium oxide and/or one or more rare earth oxides (e.g., cerium dioxide) and/or magnesium oxide and/or calcium oxide is partially stabilized with 0.5 to 5 mole-% of yttrium oxide an |
| 4514387 |
Chemokinesins and chemotaxins of leukocytes and inflamed tissues |
April 30, 1985 |
| The invention relates to new chemokinesins and chemotaxins of leukocytes and inflamed tissue which have the biological and physico-chemical properties stated in the patent claims. The compounds selectively influence the motility of leukocytes or selectively attract leukocytes. The in |
| 4512971 |
Mitogens of leukocytes and inflamed tissues |
April 23, 1985 |
| The invention relates to new mitogens of leukocytes and inflamed tissue which have the biological and physicochemical properties stated in the claims. The compounds selectively induce the division and differentiation of leukocytes and their precursors in the bone marrow. The invention al |
| 4512970 |
Chemorecruitins of leukocytes and inflamed tissues |
April 23, 1985 |
| The invention relates to new chemorecruitins of leukocytes and inflamed tissue which have the biological and physicochemical properties stated in the patent claims. The compounds selectively induce a leukocytosis reaction and/or a leftward shift reaction in vivo. The invention also r |
| 4452735 |
Leukorecruitin |
June 5, 1984 |
| The invention relates to SERUM-DERIVED "LEUKORECRUITIN", which is A PROTEIN MEDIATOR OF INFLAMMATION FROM MAMMALIAN SERUM specifically inducing positive leukocytosis reaction and leukocyte recruitment from the bone marrow into the blood of animals and humans without biological side-r |
| 4343793 |
Process for obtaining intact and viable leucocytes and thrombocytes from blood |
August 10, 1982 |
| A process for obtaining functionally and morphologically intact and viable leucocytes and thrombocytes from blood is disclosed. Erythrocytes are removed from the blood and then the leucocytes are separated by centrifugation and treated to remove trace amounts of erythrocytes and thro |
| 4263115 |
Ion-selective electrode device for polarographic measurement of oxygen |
April 21, 1981 |
| An ion-selective electrode device for measuring oxygen concentrations comprises a noble metal reduction electrode connected to a voltage source; a reference electrode connected to said reduction electrode; an ion-selective carrier or ligand membrane disposed in front of the reduction |
| 4241738 |
Spectral photometer for medical use in determining skin coloration |
December 30, 1980 |
| A housing contains a light source, a monochromator, a photosensitive unit and an oscilloscope-type display. A flexible bundle of fiber-optic elements extends from within the housing out, and is provided at its outer end with a spacing ring. The spacing ring is placed against a skin s |
| 4117117 |
Tridecapetide having gastrin effect |
September 26, 1978 |
| The tridecapeptide having the general formula L-leucyl-L-glutamyl-L-glutamyl-L-glutamyl-L-glutamyl-L-glutamyl-L-alanyl-L -tyrosylglycyl-L-tryptophyl-L-leucyl-L-asparagyl-L-phenylalanineamide, or a salt or protected derivative thereof. Such tridecapeptide has gastrin activity. A proces |
